Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SYM004 |
Synonyms | |
Therapy Description |
Symphogen (Sym004) is comprised of two antibodies (Futuximab and Modotuximab) that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (PMID: 31959764, PMID: 31679083). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SYM004 | Symphogen | EGFR Antibody 60 | Symphogen (Sym004) is comprised of two antibodies (Futuximab and Modotuximab) that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (PMID: 31959764, PMID: 31679083). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS mutant | colorectal cancer | predicted - resistant | SYM004 | Preclinical - Pdx | Actionable | In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). | 29423521 |
BRAF mutant | colorectal cancer | predicted - resistant | SYM004 | Preclinical - Pdx | Actionable | In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). | 29423521 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03549338 | Phase II | Modotuximab Futuximab SYM004 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | Terminated | USA | ITA | ESP | DEU | 0 |
NCT02540161 | Phase II | SYM004 | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT02083653 | Phase II | SYM004 Fluorouracil Capecitabine | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | Completed | USA | POL | ITA | HUN | FRA | ESP | DEU | BEL | AUT | 1 |
NCT02965417 | Phase II | SYM004 | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients | Withdrawn | 0 |